Sun Pharmaceutical Industries

One of the world’s leading generics manufacturers — Indian Sun Pharmaceutical Industries (Sun Pharma) — has announced the purchase of 85.1% of shares of Biosintez making part of Biotech pharmaceutical holding. Biotech representative has confirmed the transaction. The transaction amount accounts for $60 mln, including Russian company’s $36 mln debt assumed by Sun Pharma, according to the information provided by the latter.

24 November 2016
60.0 mln
Penza Region

Investor profile

Sun Pharmaceutical Industries


Company's website:

T: +91 22 4324 4324

Public Company


Contact: ISRAEL MAKOV, Chairman of Board of Directors

Sun Pharma is the leading Indian pharmaceutical company that has consistently ranked in the global TOP 5 generics manufacturers. Sun Pharma has 47 facilities located on 6 continents, R&D centres distributed around the world, and multi-cultural employees representing more than 50 nationalities. Company’s overall revenue for a 12-month period until March 2016 inclusive accounted for about $4.3 bln, of which the US market share accounts for $2.1 bln. The Company occupies a leading position among 12 categories of Indian physicians representing 32 brands in India’s TOP 300 pharmaceutical brands. The Company is represented in over 100 emerging markets and 6 markets of Western Europe. Company’s business in the OTC segment is in TOP 10 in 4 world markets. Company’s business in the API segment is based on 14 top-class facilities worldwide.